Literature DB >> 16401825

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients.

Nicola Giuliani, Francesca Morandi, Sara Tagliaferri, Simona Colla, Sabrina Bonomini, Gabriella Sammarelli, Vittorio Rizzoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16401825     DOI： 10.1182/blood-2005-07-2719

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

Review 2.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

3.  Bone anabolic agents for the treatment of multiple myeloma.

Authors:  Sonia Vallet; Noopur Raje
Journal:  Cancer Microenviron       Date:  2011-12-03

4.  Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Authors:  B Dalla Palma; D Guasco; M Pedrazzoni; M Bolzoni; F Accardi; F Costa; G Sammarelli; L Craviotto; M De Filippo; L Ruffini; P Omedè; R Ria; F Aversa; N Giuliani
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

Review 5.  Bone-immune cell crosstalk: bone diseases.

Authors:  Giorgio Mori; Patrizia D'Amelio; Roberta Faccio; Giacomina Brunetti
Journal:  J Immunol Res       Date:  2015-04-27       Impact factor: 4.818

6.  The role of HuR in the post-transcriptional regulation of interleukin-3 in T cells.

Authors:  José A González-Feliciano; Marimar Hernández-Pérez; Luis A Estrella; Daisy D Colón-López; Armando López; Marina Martínez; Kirla R Maurás-Rivera; Clarivel Lasalde; Daviana Martínez; Félix Araujo-Pérez; Carlos I González
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

Review 7.  Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.

Authors:  Samuel S McCachren; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 8.  Cellular mechanisms of multiple myeloma bone disease.

Authors:  Angela Oranger; Claudia Carbone; Maddalena Izzo; Maria Grano
Journal:  Clin Dev Immunol       Date:  2013-05-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.